To ensure higher drug prices for medicines in short supply, the Ministry of Health and Welfare (MOHW) announced its plan to revise the evaluation standard for drugs eligible to apply for pricing adjustments to increase the upper limit price (list price).

Accordingly, national essential drugs and those selected by public-private consultative bodies as having unstable supply will be eligible to apply for price increase adjustments.

According to industry sources on December 4th, the MOHW is reviewing a plan to include national essential drugs and drugs suggested to be in short supply by its public-private consultative body as subjects in its evaluation standard to adjust the upper